Rebiotix Senior Management
Our dedicated team with deep experience in the pharmaceutical and medical device industries provide the leadership needed to manufacture, develop, and advance Ferring’s live biotherapeutic products platform. Their passion for addressing patient needs drives the clinical and scientific innovation that is the hallmark of Ferring’s programs – read on to learn more about our Roseville team:
Greg Fluet, Chief Operating Officer and Site Head
Greg Fluet is the Chief Operating Officer and Site Head for Rebiotix, a Ferring Company. Mr. Fluet has been on the team at Rebiotix since 2016, including serving as Chief Business Officer until its acquisition by Ferring Pharmaceuticals in April 2018.
Prior to joining the microbiome space, Mr. Fluet had a strategic consulting practice focusing on startup life science companies. He also serves on the board of Electromed (NYSE: ELMD), a medical device company focused on airway clearance technologies. He had previously served as Chief Executive Officer at Urologix, Inc., then a public company, from 2012 to January 2016. He also served as its interim Chief Financial Officer from August 2014 to May 2015, and as its Executive Vice President and Chief Operating Officer from 2008 to 2012. Prior to Urologix, Mr. Fluet served as an associate at Sapient Capital Management, LLC, a healthcare focused venture capital fund. He received his Bachelor of Science degree in Mechanical Engineering from Stanford University.
Ken F. Blount, PhD, Chief Scientific Officer and Vice President of Microbiome Research
Ken Blount, PhD, is the Chief Scientific Officer for Rebiotix Inc., a Ferring Company, as well as Ferring’s Vice President of Microbiome Research. Dr. Blount is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics.
Prior to joining Rebiotix/Ferring, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridioides difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.
Lindy Bancke, PharmD, VP, Global Clinical Operations US
Lindy Bancke, PharmD, is the Vice President of Global Clinical Operations – United States for Ferring Pharmaceuticals. Formerly the Head of Clinical Development at Rebiotix, Dr. Bancke spearheaded the company’s microbiome therapeutics program, which led to the FDA approval of Ferring’s first-in-class microbiota-based live biotherapeutic product.
Dr. Bancke joined Rebiotix in 2018 with a strong background in clinical development and strategic leadership at biotech and mid-size pharmaceutical companies. Her clinical and program leadership experience spans first-in-human studies to global Phase 3 trials, as well as products with orphan designation, fast track status, and unique regulatory pathways.
Prior to joining Rebiotix, Dr. Bancke spent 10 years at Upsher-Smith Laboratories, leading clinical trials and research strategy, as well as cross-functional development programs for both ANDA and NDA products. Most recently, she was the Clinical and Development Program Lead at Proximagen, a privately-held biotech company focused on small molecule drug discovery and development. At Proximagen, Dr. Bancke led an early-phase neuro-oncology program, as well as a late-stage epilepsy product preparing for NDA submission. Dr. Bancke received her undergraduate degree in biology from the University of Nebraska–Lincoln and earned a PharmD from the University of Nebraska Medical Center, after which she completed a post-doctoral fellowship in clinical research.
Tom Willard, MBA, VP of Upstream Marketing and Market Strategy
Tom Willard, MBA, is the Vice President of Upstream Marketing and Market Strategy for Rebiotix Inc., a Ferring Company. Mr. Willard brings over 30 years of commercial experience to the team. Mr. Willard’s experience covers a variety of therapeutic areas, including gastroenterology, infectious disease, urology, CNS/Neurology, oncology, immunology, and Women’s Health.
Mr. Willard has led commercial teams for pre-launch, launch, and co-promotion initiatives for both large and small companies in the pharmaceutical and biotech arenas, as well as providing commercial strategy to improve a company’s value. Additionally, Mr. Willard’s experience includes strategic brand planning, business development, market research, and product platform strategy as part of pre-approval packages, new market entries and product life cycle management.
Mr. Willard received his undergraduate degree in Microbiology and Immunology from Purdue University, as well as his MBA in Marketing/Corporate Strategy from Clemson University.
Mark King, MS, Senior Director of Research and Development
Mark King, MS, is the Senior Director of Research and Development at Rebiotix Inc., a Ferring Company. Mr. King brings over 25 years biotech industry experience to the team, with his work ranging from experience with proteins and peptides to blood products and small molecules.
Mr. King is also well-versed in product development technologies, including fermentation, formulation and assay development, all under the umbrella of International Council for Harmonization (ICH) guidelines and Quality by Design (QbD) programs. These arenas lend well to Mr. King’s leadership in developing the Chemistry, Manufacturing and Controls (CMC) documents needed to bring new microbiome-based technologies forward to regulatory agencies as part of the product approval process.
Prior to joining Rebiotix, Mr. King held a range of positions in Research, Quality, and Technical Operations, supporting the missions of large and small corporations, including BioThera and MannKind Corporation. Mr. King is also the founder of Sand Dollar Consulting, LLC, specializing in process development, phase-appropriate quality systems and CMC regulatory submissions for early stage biologic products.
Mr. King received his undergraduate degree in Biochemistry from Virginia Tech, and his Masters of Science in Biochemical Engineering from the Massachusetts Institute of Technology.
Debbora Markus, Senior Director of Quality
Debbora Markus is the Sr. Director of Quality at Rebiotix Inc., a Ferring Company, where she leads four functional teams in advancing ground-breaking microbiota-based therapeutics including; Quality Systems and Compliance, Quality Operations, Clinical Quality and Compliance and Quality Control. Ms. Markus has over 25 years of various Quality leadership roles leading teams in the Pharmaceutical, Biologic and Medical device industries.
Prior to joining Rebiotix, she held multiple Quality leadership positions at Integer Holdings, driving product approvals and compliance initiatives for Class III, II and combination products. As part of her extensive experience, Ms. Markus also spent 15 years in the generic Rx pharmaceutical industry at Perrigo, formerly Paddock laboratories, including roles from QC Microbiology to leading Quality Commercial Operations with a focus on leading teams to provide Quality oversight and delivery of new product approvals from product development to commercialization.
Ms. Markus obtained her Bachelor of Science degree in Microbiology and Chemistry from North Dakota State University, in Fargo, ND. Ms. Markus’s passion is to maximize results and improvements, while building relationships with people to achieve complex, strategic and on-time results.
Sara Wall, Senior Director, Technical Operations
Sara Wall is the Senior Director, Technical Operations at Rebiotix Inc., a Ferring Company, where she leads the team comprised of Production, Supply Chain, Donor Program, Engineering and their supporting functions. She has a passion for developing and leading teams focused on maximizing the skill sets of each individual to achieve results.
Prior to joining Rebiotix, Ms. Wall led the Operations team at DiaSorin Inc, an Invitro-Diagnostics company. Through many roles and responsibilities, from Reagent Manufacturing to Quality Control, Tech Transfer and Engineering, she spent her career successfully transferring newly developed products into industrial scale manufactured products, developing and leading great people along the way.
Ms. Wall obtained her Master of Science degree in Manufacturing System Engineering from the University of St. Thomas, in St. Paul, MN. A dream of being a scientist starting in the 4th grade led her to complete her undergraduate work in Biotechnology at the University of Minnesota – Mankato working in a diabetes research laboratory.